Garenoxacin Approval Status
Garenoxacin is an investigational broad-spectrum quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections.
In August 2006, Schering-Plough Corporation announced the withdrawal of the New Drug Application (NDA) for garenoxacin.
Development Status and FDA Approval Process for Garenoxacin
|Feb 13, 2006||Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.